Idiopathic thrombocytopenic purpura (itp) and Primary myelofibrosis
Summary:
Primary myelofibrosis is found among people with Idiopathic thrombocytopenic purpura (itp), especially for people who are female, 60+ old.
The study analyzes which people have Primary myelofibrosis with Idiopathic thrombocytopenic purpura (itp). It is created by eHealthMe based on reports of 108 people who have Idiopathic thrombocytopenic purpura (itp) from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
108 people who have Idiopathic Thrombocytopenic Purpura (Itp) and Primary Myelofibrosis are studied.
What is Idiopathic thrombocytopenic purpura (itp)?
Idiopathic thrombocytopenic purpura (itp) (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting) is found to be associated with 1,168 drugs and 1,029 conditions by eHealthMe.
What is Primary myelofibrosis?
Primary myelofibrosis (primary disorder of the bone marrow) is found to be associated with 1,087 drugs and 768 conditions by eHealthMe.
Number of Primary myelofibrosis in Idiopathic thrombocytopenic purpura (itp) reports submitted per year:
/primary myelofibrosis/would-you-have-primary-myelofibrosis-when-you-have-idiopathic-thrombocytopenic-p.png "Would you have Primary myelofibrosis when you have Idiopathic thrombocytopenic purpura (itp)?")
Gender of people who have Idiopathic thrombocytopenic purpura (itp) and experienced Primary myelofibrosis *:
Age of people who have Idiopathic thrombocytopenic purpura (itp) and experienced Primary myelofibrosis *:
Common co-existing conditions for these people *:
Common drugs taken by these people *:
Common symptoms for these people *:
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Primary myelofibrosis?
Check whether Primary myelofibrosis is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
Treatments, associated drugs and conditions:
- Idiopathic thrombocytopenic purpura (itp) (14,094 reports)
- Primary myelofibrosis (35,056 reports)
COVID vaccines that are related to Primary myelofibrosis:
- Primary myelofibrosis in Moderna COVID Vaccine
- Primary myelofibrosis in Pfizer BioNTech Covid Vaccine
- Primary myelofibrosis in Johnson and Johnson Covid Vaccine
Common drugs associated with Primary myelofibrosis:
- Jakafi: 776 reports
- Aspirin: 275 reports
- Hydrea: 264 reports
- Lopurin: 171 reports
- Allopurinol: 171 reports
- Exjade: 156 reports
- Nplate: 155 reports
- Prednisone: 152 reports
- Hydroxyurea: 141 reports
- Prednisolone: 141 reports
All the drugs that are associated with Primary myelofibrosis:
- Primary myelofibrosis (1,087 drugs)
Common conditions associated with Primary myelofibrosis:
- High blood pressure: 137 reports
- Idiopathic thrombocytopenic purpura (itp): 108 reports
All the conditions that are associated with Primary myelofibrosis:
- Primary myelofibrosis (768 conditions)
How the study uses the data?
The study is based on Primary myelofibrosis and Idiopathic thrombocytopenic purpura (itp), and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Multiple Sclerosis Aggravated and Neurogenic Bladder - 5 seconds ago
- Loraz and Sugammadex drug interaction - 5 seconds ago
- Kidney Stones and Paranasal Sinus Hypersecretion - 7 seconds ago
- Haematuria and Haematemesis - 9 seconds ago
- Polycythemia Vera and Skin Reaction - 12 seconds ago
- Zolpidem and Calcitonin-Salmon drug interaction - 17 seconds ago
- Arnuity Ellipta and Tachycardia Aggravated - 18 seconds ago
- Dizziness and Atrioventricular Block - 20 seconds ago
- Parkinson'S Disease and Strangulated Hernia - 20 seconds ago
- Graft Versus Host Disease In Skin and Acute Lymphocytic Leukaemia Recurrent - 21 seconds ago